Drug Trial Radar · NCT06656091
A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Oct 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Oct 31, 2024
Primary completion
Jan 30, 2027
Study completion Jan 30, 2027
Sponsor
- Lead sponsor
- Shanghai Runshi Pharmaceutical Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the overall survival of simmitinib versus investigator's choice of chemotherapy for Participants with advanced or metastatic oesophageal squamous cell carcinoma who have disease progression after first-line standard therapy.
Conditions
- Advanced Oesophageal Squamous Cell Carcinoma
Interventions
simmitinibDrug
simmitinib 6mg,QD ,3 weeks on 1 week off
investigator's choice of chemotherapy,include docetaxel or irinotecan.Drug
docetaxel injection 75mg/m\^2,d1,every 3 weeks or ilinotecan injection 180mg/m\^2,d1,every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- OSTime frame: up to approximately 3 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.